Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-initiated phase I/II trial in PLX-PAD cell therapy for the treatment of steroid-refractory chronic Graft-versus-Host-Disease (GvHD)

Next Previous
X
Search
Trial Profile

An investigator-initiated phase I/II trial in PLX-PAD cell therapy for the treatment of steroid-refractory chronic Graft-versus-Host-Disease (GvHD)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions

    • Most Recent Events

    • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
    • 13 Oct 2020 According to a Pluristem Therapeutics media release, based on these results, the study was approved to commence enrollment of 14 patients in cohort II to be treated with 4 injections of 150 million cells.
    • 13 Oct 2020 Results published in the Pluristem Therapeutics media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top